Health Care & Life Sciences » Pharmaceuticals | Clearside Biomedical Inc.

Clearside Biomedical Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,909.00
8,269.00
20,283.00
83,631.00
37,640.00
40,878
Other Current Assets
108.00
54.00
199.00
686.00
1,561.00
2,066
Total Current Assets
2,017.00
8,323.00
20,482.00
84,317.00
39,201.00
42,944
Net Property, Plant & Equipment
98.00
205.00
156.00
94.00
885.00
790
Total Investments and Advances
-
-
-
360.00
360.00
360
Other Assets
22.00
1,771.00
417.00
42.00
47.00
26
Total Assets
2,137.00
10,299.00
21,055.00
84,813.00
40,493.00
44,120
ST Debt & Current Portion LT Debt
-
-
1,733.00
-
3,200.00
Accounts Payable
248.00
-
-
-
5,384.00
Other Current Liabilities
435.00
2,424.00
3,463.00
5,408.00
4,935.00
Total Current Liabilities
683.00
2,424.00
5,196.00
5,408.00
13,519.00
Long-Term Debt
268.00
-
4,243.00
7,586.00
4,809.00
Other Liabilities
53.00
253.00
961.00
160.00
750.00
Total Liabilities
1,004.00
2,677.00
10,400.00
13,154.00
19,078.00
Common Equity (Total)
10,738.00
19,213.00
36,659.00
71,659.00
21,415.00
Total Shareholders' Equity
1,133.00
7,622.00
10,655.00
71,659.00
21,415.00
Total Equity
1,133.00
7,622.00
10,655.00
71,659.00
21,415.00
Liabilities & Shareholders' Equity
2,137.00
10,299.00
21,055.00
84,813.00
40,493.00
Preferred Stock (Carrying Value)
11,871.00
26,835.00
47,314.00
-
-

About Clearside Biomedical

View Profile
Address
900 North Point parkway
Alpharetta Georgia 30005
United States
Employees -
Website http://www.clearsidebio.com
Updated 07/08/2019
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H.